Eli Lilly Launches AI Drug Discovery Program Backed by Rhino Federated Computing
Today, Eli Lilly announced the launch of their TuneLab program, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly's research data. At the same time, selected biotech partners contribute training data, which fuels continuous improvement.
TuneLab integrates with Rhino FCP’s generative-AI-powered workflows, federated dataset & compute apps, and federated trusted research environments (fTRE), complemented by LLM-driven interfaces and cloud analytics services.
Now live with numerous biotech partners and ready-to-use models available for immediate use across discovery and pre-clinical workflows, the program is quickly demonstrating how federated AI can shift the paradigm on what drug development partnership can and should look like.
